PolyPid

D-PLEX100:
Let The Recovery Begin. A first-in-class incisional SSI prophylactic therapy engineered to extend protection throughout the critical postoperative recovery period.

Resources page. Press Release, News, cientific Publications, Events.

Reduction in local tumor recurrence in a murine R2 resection model comparing locally administered docetaxel-releasing product, OncoPLEX, versus systemic docetaxel

Potent antibacterial activity in surgical wounds with local administration of D-PLEX100

Effect of local prolonged-release incisional doxycycline on surgical site infection prophylaxis in abdominal colorectal surgery: the SHIELD 1 randomized clinical trial

Preclinical In-Vivo Safety and Toxicokinetics of D-PLEX100 in an Abdominal Surgery Incision Model in Juvenile Miniature Swine

PolyPid appointed Dikla Czaczkes Akselbrad as Chief Executive Officer in 2021 after she served as Executive Vice President and Chief Financial Officer since 2017, overseeing the company’s Nasdaq Global Market IPO in June 2020.

Dr. Hagai has 20 years of experience in corporate marketing and business development roles at major pharmaceutical companies. He previously served as Vice President of Business Development for a biotech company at Aurum Ventures before joining PolyPid.

Ms. Rubin has 17 years of leadership experience in pharmaceutical and biotech operations and quality. She previously held roles at PolyPid and Teva Pharmaceuticals, including Vice President of Quality Affairs and Quality Control Director.

Delivering Control. PolyPid empowers surgeons with greater control over surgical site care, gives patients confidence throughout their recovery.

PolyPid is a biopharmaceutical company focused on developing long-acting treatments to improve patient outcomes.

PolyPid Ltd. aims to make its website accessible to people with disabilities, implementing measures to support usability.

PolyPid reports its **D-PLEX100** drug candidate is under **FDA Priority Review** with a **PDUFA goal date of November 28, 2026**. The company continues preparing for a potential U.S. commercial launch while providing a corporate update and third-quarter financial results.

Nov 2026GlobeNewswireNews article

PolyPid introduces **PD01B**, a new antibiotic treatment candidate using its **Kynatrix technology** to deliver localized, controlled-release therapy for **diabetic foot infections**. The product leverages PolyPid’s proprietary platform to address a high-unmet need in wound care. This expansion follows the company’s existing pipeline efforts in antibiotic innovation.

Oct 2026GlobeNewswireNews article

The **European Medicines Agency (EMA)** validates PolyPid’s **Marketing Authorization Application (MAA)** for **D-PLEX100**, confirming the submission is complete. The agency now initiates a formal review of the therapy’s application. PolyPid develops **immuno-oncology treatments** targeting solid tumors.

Oct 2026GlobeNewswireNews article

PolyPid has regained exclusive commercialization rights for its D-PLEX100 product in Europe after terminating its 2022 agreement with ADVANZ PHARMA. The move expands PolyPid’s global commercialization opportunities for the drug candidate. D-PLEX100 is a potential treatment under development by PolyPid.

Oct 2026GlobeNewswireNews article